Skip to main content

Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

The Original Article was published on 25 May 2021

Correction to: Molecular Autism (2021) 12:38 https://doi.org/10.1186/s13229-021-00447-5

Following publication of the original article [1], the authors pointed out that the part of the text in Methods part was incorrectly stipulated and should read as follows:

We were unable to produce or obtain SF-rich preparations for this study like those used in our previous study [6]. Based on prior testing of alternative preparations [25–27], we used commercially available crushable tablets containing broccoli seed and sprout extracts as a source of GR (equivalent to 34 µmol GR calculated to yield at least ~ 15 µmol SF) and active myrosinase enzyme. Tablets commercially produced as Avmacol® were provided by Nutramax Laboratories, Inc., Edgewood, MD. Placebo tablets, identical in size and similar in appearance to the active tablets, contained microcrystalline cellulose, red, yellow and black coloring and magnesium stearate, and were produced by Dr. Stephen Hoag, University of Maryland Department of Pharmacy.

Reference

  1. Zimmerman AW, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021;12:38. https://doi.org/10.1186/s13229-021-00447-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Author notes

  1. Deceased: Li-Ching Lee.

    • Li‑Ching Lee
Authors

Corresponding author

Correspondence to Andrew W. Zimmerman.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zimmerman, A.W., Singh, K., Connors, S.L. et al. Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Molecular Autism 12, 44 (2021). https://doi.org/10.1186/s13229-021-00451-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13229-021-00451-9